Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted
therapy has replaced radiation therapy and chemotherapy as the main treatment option for …

Context: The number of prognostic markers for clear cell renal cell carcinoma (ccRCC) has
been increasing regularly over the last 15 years, without being integrated and compared …

Background Renal cell carcinoma (RCC) is a deadly urological tumor that remains largely
incurable. Our limited understanding of key molecular mechanisms underlying RCC …

Acquired and intrinsic resistance to receptor tyrosine kinase inhibitors (RTKi) represents a
major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC) …

Background Anti-PDL-1 immunotherapy for Hepatocellular Carcinoma (HCC) demonstrated
a mixed response. Polycomb Repressor Complex 2 (PRC2) contributes to the initiation and …

Simple Summary Medulloblastoma is the most common malignant childhood brain tumour.
Under standard therapy, relapse occurs in 30% of patients and is almost universally fatal …

VHL mutations are the most common tumorigenic lesions in clear cell renal cell carcinoma
(ccRCC) and result in continued activation of the HIF/VEGF pathway and uncontrolled …

RNA therapy is a disruptive technology comprising a rapidly expanding category of drugs.
Further translation of RNA therapies to the clinic will improve the treatment of many diseases …

The aim of the current study was to investigate the role of enhancer of zeste 2 polycomb
repressive complex 2 subunit (EZH2) in the progression of bladder cancer. Human bladder …

Among urological tumors, renal cell carcinoma (RCC) is the third-highest mortality rate
tumor, and 20%–30% of RCC patients present with metastases at the time of diagnosis …